 FREMONT, CA, Sept. 01, 2021 GLOBE NEWSWIRE -- via NewMediaWire ABVC BioPharma, Inc. NASDAQ: ABVC, a clinical stage biopharmaceutical company developing therapeutic solutions in oncologyhematology, CNS, and ophthalmology, today announced it has filed new PCT Patent Cooperation Treaty applications in connection with its medicines that treat major depressive disorder MDD and Attention-Deficit Hyperactivity Disorder ADHD. The two PCT applications describe the treatment methods of oral administrating compositions containing Radix Polygalae Polygala tenuifolia Willd extract PDC-1421. PDC-1421 is the active ingredient for both the companys MDD and ADHD drugs. 